Lana Ganoci

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 15

Top Topics

Oxide Nanoparticles

Percutaneous Coronary Intervention

Replacement Therapy

Genome Wide Analysis

Top Venues

Pharmacogenomics

The pharmacogenomics journal

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Lana Ganoci, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, Tamara Božina
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes 15 (5) (2024)
Lana Ganoci, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, Tamara Božina
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes 15 (5) (2024)
Lana Ganoci, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, Tamara Božina
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes 15 (5) (2024)
Lana Ganoci, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, Tamara Božina
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes 15 (5) (2024)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Livija Šimičević, Iva Canjuga, Lada Zibar, Ana Borić-Bilušić, Lana Ganoci, Nada Božina
Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes. Journal of clinical pharmacy and therapeutics 47 (9) (2022)
Iveta Merćep, Ivana Radman, Vladimir Trkulja, Tamara Božina, Livija Šimičević, Ema Budimir, Lana Ganoci, Nada Božina
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. European journal of clinical pharmacology (2021)
Nada Božina, Ivan Bilić, Lana Ganoci, Livija Šimičević, Stjepko Pleština, Lucija Lešnjaković, Vladimir Trkulja
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology (2021)
Dina Bosnjak Kuharic, Nada Bozina, Lana Ganoci, Porin Makaric, Ivana Kekin, Nikola Prpic, Tamara Bozina, Martina Rojnic Kuzman
Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. The pharmacogenomics journal 20 (5) (2020)
Lana Ganoci, Tamara Božina, Nikica Mirošević Skvrce, Mila Lovrić, Petar Mas, Nada Božina
Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug metabolism and personalized therapy 32 (1) (2017)